Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Variants & evidence
522 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ABL1 M388L1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4707In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 M472I1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4723In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Non-P-Loop Mutation2 | |||||||
| Bosutinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6337In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6998This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| ABL1 P441L1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4716In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 P480L1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4724In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 P-Loop Mutation3 | |||||||
| Bosutinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6336In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | B | Does Not Support Resistance | 2 | accepted | EID6997This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | accepted | EID8094In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Of 14 patients who started the study in late chr… | |
| ABL1 S417Y1 | |||||||
| Imatinib | Predictive | C | Supports Resistance | 2 | rejected | EID8089In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Among 64 patients initially in late-chronic phas… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| ABL1 S438C1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4435In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 T315I4 | |||||||
| Asciminib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11225In phase 1, dose-escalation trial 141 patients with chronic-phase chronic myeloid leukemia (CML) and 9 patients with accelerated-phase CML who had previously taken at least two ATP-competitive tyrosin… (full text at CIViC) PMID 31826340 · Hughes et al., 2019 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Resistance | 2 | rejected | EID6284In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Resistance | 3 | rejected | EID6195In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … | |
| ABL1 TKD Mutation4 | |||||||
| Bosutinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6335In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6996This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6311This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … | |
| ABL1 V289I1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4697In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 V379I1 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4704In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 Y232S1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4688In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Y342H1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4698In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 Y393C1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | — | submitted | EID4708In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| BCL2L11 Alternative splicing1 | |||||||
| Imatinib | Predictive | D | Supports Resistance | 4 | submitted | EID9699Primary imatinib resistance is caused by a deletion polymorphism in intron 2 (see EID 1280 and 1281). An in vitro study shows that the deletion biases BIM splicing from exon 4 to exon 3. Adding ASOs t… (full text at CIViC) PMID 29100409 · Liu et al., 2017 · Open in CIViC | civic |
| BCL2L11 Deletion Polymorphism2 | |||||||
| Imatinib | Predictive | B | Supports Resistance | 4 | accepted | EID1280DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in … (full text at CIViC) PMID 22426421 · Ng et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID9701In a clinical study including 200 patients, deletion polymorphism is not significantly associated with resistance to imatinib (p = 0.116). PMID 25295932 · Chen et al., 2014 · Open in CIViC | civic |
| ABL1 Fusion13 | |||||||
| (diagnostic) | Diagnostic | A | Supports Positive | 4 | accepted | EID220In this 2010 review, the authors highlighted the central diagnostic and pathogenic role of the BCR::ABL1 fusion gene in Chronic Myeloid Leukemia (CML), emphasizing that its presence is the characteriz… (full text at CIViC) PMID 20537386 · An et al., 2010 · Open in CIViC | civic |
| (prognostic) | Prognostic | B | Supports N/A | 4 | submitted | EID12434Whole-genome sequencing of single-cell-derived hematopoietic clones from chronic myeloid leukemia (CML) patients revealed that the BCR::ABL1 fusion is acquired 3 to 14 years prior to clinical diagnosi… (full text at CIViC) PMID 40205062 · Kamizela et al., 2025 · Open in CIViC | civic |
| (diagnostic) | Diagnostic | B | Supports Positive | 4 | accepted | EID12526In this 2016 study, the authors analyzed 398 newly diagnosed Chronic Myeloid Leukemia (CML) patients, identifying 12 (3%) cases that lacked the Philadelphia (Ph) chromosome by conventional cytogenetic… | |
| ABL1 A365V + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4700In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 A366G + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4701In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| ABL1 A397P + ABL1 Fusion3 | |||||||
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4709In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4710In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID7034In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytog… | |
| ABL1 D276G + ABL1 Fusion5 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4360In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with … (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4357In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4356In an in vitro study, a Ba/F3 murine cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment… | |
Data updated 23 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 12623848 · Branford et al., 2003 · Open in CIViC
| civic |
PMID 16772610 · Bradeen et al., 2006 · Open in CIViC
| civic |
| Ponatinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11226In a phase 2, dose-reduction trial, 282 patients were enrolled who had previously been treated with at least 2 prior TKIs or had a T315I mutation. Efficacy was assessed on an interim analysis based on… (full text at CIViC) PMID 34407543 · Cortes et al., 2021 · Open in CIViC | civic |
PMID 19779040 · Müller et al., 2009 · Open in CIViC
| civic |
| Nilotinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6342In this open-label, phase II registration trial, patients that were imatinib resistant (n = 192) or intolerant (n = 89) underwent nilotinib monotherapy. Prior to nilotinib treatment, 105 and 9 patient… (full text at CIViC) PMID 19652056 · Hughes et al., 2009 · Open in CIViC | civic |
PMID 28404889 · Luatti et al., 2017 · Open in CIViC
| civic |
| 〃 | Diagnostic | B | Supports Positive | 4 | accepted | EID12589In this 2009 study, the authors included 336 chronic myeloid leukemia (CML) patients at diagnosis, of which 25 patients (7.44%) exhibited variant Philadelphia (Ph) chromosome translocations. A control… (full text at CIViC) PMID 19737651 · Bennour et al., 2009 · Open in CIViC | civic |
| 〃 | Diagnostic | C | Does Not Support Positive | 2 | accepted | EID213Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is no… (full text at CIViC) PMID 25212276 · Schmidt et al., 2014 · Open in CIViC | civic |
| Asciminib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11223233 patients aged 18 or older who had Ph+ CML and were previously treated with two or more tyrosine kinase inhibitors were recruited to an open-label, multicentre phase 3 trial. The patients were rand… (full text at CIViC) PMID 34407542 · Réa et al., 2021 · Open in CIViC | civic |
| 〃 | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12213In the phase 3 ASC4FIRST trial (NCT04971226), patients with newly diagnosed Ph+ CML were randomized 1:1 to receive either asciminib (n=201) or an investigator-selected TKI (n=204). At week 48, major m… (full text at CIViC) PMID 38820078 · Hochhaus et al., 2024 · Open in CIViC | civic |
| Bosutinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11224536 patients with CML, 487 of which were Philadelphia chromosome-positive were enlisted to a multicentre, open-label phase 3 trial assessing the efficacy and safety of bosutinib. The patients were ran… (full text at CIViC) PMID 29091516 · Cortes et al., 2018 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID4706Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated us… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| Imatinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID260The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML. PMID 20537386 · An et al., 2010 · Open in CIViC | civic |
| 〃 | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID344BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens. PMID 20537386 · An et al., 2010 · Open in CIViC | civic |
| Dasatinib + NilotinibSubstitutes | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID261The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval. PMID 20537386 · An et al., 2010 · Open in CIViC | civic |
| Bafetinib + Dasatinib + NilotinibSubstitutes | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID7838In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM).… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC | civic |
PMID 17264298 · Guilhot et al., 2007 · Open in CIViC
| civic |
PMID 19075254 · Redaelli et al., 2009 · Open in CIViC
| civic |
| Dasatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4359This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4358In an in vitro study, a Ba/F3 cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 2.63nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |